GNOMX Corp. has been awarded a $749,700 contract by the Division of Research, Innovation, and Ventures (DRIVe) within the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) of the U.S. Department of Health and Human Services. The contract will support the development of an immune dysregulation host-based assay on a CLIA lab-compatible PCR instrument to predict risk of post-discharge deterioration and hospitalization readmission of sepsis patients.